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IL-4 or B cell stimulating factor is a polypeptide that was originally described,
in murine models ofB cell response, as a costimulant with anti-IgM antibody for
the entry of resting B cells into the S phase of the cell cycle (1) . Recent studies have
shown that IL-4 is associated with multiple biologic activities . IL-4 increases the
expression of class II MHC molecules on resting B cells (2, 3) and promotes IgGl
and IgE production by LPS preactivated B cells (4, 5) . Although initially believed
to be principally active on B cells, IL-4 has been shown to act on normal T cells
(6, 7),T cell lines (7-9), mast cell lines (10), and hematopoietic lineage cells (11, 12) .
Recently, theisolationo£ acDNA sequence coding forhumanIL-4 hasbeen reported
(13) . Human IL-4 is able to promote the growth of activated normal B cells (14),
of activatedT cells (15), and to induce the expression ofCD23 antigen on normal
B cells (16) .
Monoclonal lymphocytes from B-type chronic lymphocytic leukemia (B-CLL) t
patients canrespond to some growth factors (17, 18). Theanalysis ofthis responsive-
ness is importantto define the pattern ofreactivity ofthese malignant cellsto physi-
ological signals . In addition, the use ofmonoclonal B cells frozen at a given stage
of differentiation and possibly arising from a discrete B cell subset may help in the
understanding of the effects of interleukins . This work was designed to define the
effects of IL-4 on these B-CLL lymphocytes . We thus studied the effects of IL-4
on apanel ofB lymphocytesfrom 12B-CLL patients . Inno instance did IL-4 syner-
gize with anti-w antibody to supportDNA synthesis. Moreover IL-4 profoundly sup-
pressed the response to IL-2 in the 10 patients responsive to this interleukin . Thus,
IL-4 mayhave an inhibitory effecton theproliferation of selected B cell populations .
Materials and Methods
Patients.
￿
12 patients with hematological diagnosis of chronic lymphocytic leukemia were
studied . They were not treated at the time of blood drawing, except patient 11, whose lym-
phocytes were studied at several times before and after initiation of treatment with identical
results. Thepatients'mononuclear cells were >80%v positive for theCD19, CD20, and CD5
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antigens and <10% positive for the CD3 antigen. When membrane Ig could be detected,
monoclonality could be demonstrated on the basis of monotypic light chain expression.
Reagents. mAbs mouse mAb OKT3 (anti-CD3 antigen) and OKM5 were purchased from
Ortho Diagnostic Systems Inc. (Raritan, NJ). The Bl and B4 mAb (anti-CD20 and CD19
antigens, respectively) were obtained from Coulter Immunology (Margency Andilly, France).
The Leu-1 mAb (anti-CD5) was from Becton Dickinson & Co. (Mountain View, CA); the
IOT14 (anti-a chain ofthe IL-2-R CD25) was provided by Immunotech (Marseille Luminy,
France). mAb25 (19) (anti-CD23 antigen) was used at 5 pg/ml final dilution. Insolubilized
rabbit antibody specific for human w chain (anti-u antibody) was purchased from Bio-Rad
Laboratories (Richmond, CH). FITC-conjugated F(ab')z fragment of goat anti-mouse Ig was
from Tago Inc. (Burlingame, CA).
Factors.
￿
rIL-2 was a gift ofBiogen (SA, Geneva, Switzerland). The preparation used had
an estimated activity of 10' U/mg protein and contained 97.3% IL-2 by SDS-PAGE anal-
ysis. IL-4 was obtained from Dr. K. Arai (DNAX Research Institute, Palo Alto, CA) as su-
pernatants from L cells transfected with the peD or PEBT vector containing the human cDNA
clone (13). Some experiments were performed with highly purified L cell-derived IL-4. A
unit of IL-4 was defined as described previously (14). We verified the biological activity of
these IL-4 preparations on normal human B cells; when used at 50-100-U/ml concentrations,
they proved able to induce the expression of the CD23 marker, and to enhance DNA syn-
thesis in the presence of anti-Ii antibody (data not shown). A mock preparation consisting
ofculture supernatants of L cells transfected with a nonrelated cDNA was also used. Recom-
binant human IFN-y was obtained from Roussel Uclaf(Romainville, France). The prepara-
tion had a specific activity of 10' U/mg protein.
Cell Preparations.
￿
B-CLL cells were purified as follows. Mononuclear cells were isolated
from the blood of B-CLL patients by centrifugation on a Ficoll-Hypaque (Pharmacia, Upp-
sala, Sweden) gradient. T cells were eliminated by two cycles of rosetting using aminoethyl-
isothiouronium bromide-treated sheep red blood cells. These preparations were analyzed
using a FAGS TAR flow cytometer. They were homogeneous small cells, contained <0.5%
cells labeled by the OKT3 and by the OKM5 antibodies, and were devoid ofactivation markers
(17).
B Cell Proliferation Assay.
￿
Cells (105) were cultured in flat-bottomed microtest tissue cul-
ture plates (Falcon Labware, Oxnard, CA) in 0.2 ml RPMI-1640 culture medium supplemented
with 1% L-glutamine, 1% antibiotics, 2-ME (0.5 x 10-5 M), and 2 % FCS. The B cell growth
was assayed in two different systems. In the one-step assay, B cells were cultured for 3 d with
anti-g antibody (7 ug/ml) in the presence of IL-2 or IL-4. In the two-step assay, B cells were
cultured alone for 24 and 48 h with IL-2, IL-4, and with both interleukins. Cells were exten-
sively washed and cultured with factors for 3 additional days. Cells were pulsed with 0.5 PCi
of [3Hlthymidine (CEA, Saclay, France) during the last 16 h ofculture period, and incorpo-
ration of [3Hlthymidine was measured by a standard liquid scintillation counter. Cultures
were performed in duplicate and the results were expressed as the mean ofcounts per minute
per culture. All experiments were performed at least two times, and data shown were from
one representative experiment.
Fluorescence Analysis.
￿
Cells were cultured for 24 h with various factors and washed twice
before staining. 0.5 x 106 viable cells were treated with antibody at the appropriate dilu-
tion in PBS containing 2 % BSA and a 0.1 % sodium azide (PBSS/BSA/azide). After a 30-min
incubation at 4°C, the cells were washed twice in cold PBS/BSA/azide, resuspended in 50
pl of 1/10 dilution of FITC-conjugated goat F(ab')z anti-mouse Ig, and incubated for 30 min
at 4°C. Thereafter, the cells were washed twice in PBSIBSA/azide and resuspended in PBS/2 %
formaldehyde. Fluorescence analysis was performed on a FRCS TAR flow cytometer.
Results
IL-4 Has No Growth Activity on B-CLL Cells.
￿
B cells from 12 B-CLL patients were
costimulated with anti-w antibody and IL-2 or IL-4. The cells from 10 of these 12
patients were able to respond to IL-2 by an enhanced DNA synthesis. In no instanceKARRAY ET AL .
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TABLE I
IL-4 Does Not Support DNA Synthesis by B-CLL Lymphocytes
' The response was assessed on day 3 and expressed as cpm .
t In these experiments purified IL-4 was used .
S Cells were cocultured with anti-p antibody (7 pg/ml) and the indicated amounts ofinterleu-
kins, expressed as final U/ml for IL-4 and IL-2 and as final dilutions for mock (these dilu-
tions corresponded to that of 50 and 10 U/ml of IL-4, respectively) .
did IL-4 stimulateDNA synthesis in these conditions . These negative results were
obtained with IL-4 concentrations up to 100 U/ml . Data from six representative pa-
tients among responders and nonresponders to IL-2 are presented in Table I. The
same data were obtainedwhen the response was measuredonday 6 (datanot shown).
In another series ofexperiments, B-CLL cellsfrom three patients were preincubated
with anti-p antibody for 2 d, separated from the insolubilized anti-g antibody, and
cultured for 3 additional days with the same interleukins . Again, IL-4 did not en-
hanceDNA synthesis . The response of anti-g-activated cells was 1,180 f 237 cpm
in the presence of 100 U/ml of IL-4 as compared with 858 t 170 cpm in the absence
of interleukin. The same anti-g-activated cells did respond to IL-2 : 17,327 t 2,545
cpm . Inone additional patient we verified that a 2-d preculture ofB cells with IL-4
(50 U/ml) did not enhance the response to anti-g antibody in a second-step incuba-
tion (data not shown) .
IL-4 Inhibits the Response to IL-2.
￿
We then tested whether IL-4, although devoid
FIGURE 1 .
￿
IL-4 profoundly sup-
presses the response to IL-2. In the
presence of anti-It antibody cells
were cultured with IL-2 (50U/ml),
in the absence or in the presence of
IL-4 (50 U/ml) . Cultures from pa-
tients 1, 3, 4, and 5were performed
with purified IL-4. A cpm was cal-
culated on day 3 .
Interleukinss It
Response (cpm of
2 31
patient number)' :
41 5t 6z
Medium 305 339 584 519 2,789 622
IL-4 : 100 U/ml 446 586 ND ND 2,104 ND
50 U/ml 395 639 1,083 1,569 1,991 295
10 U/ml 476 860 989 1,314 2,818 332
5 U/ml 358 781 934 1,957 3,725 402
IL-2 : 50 U/ml 25,379 1,078 24,872 42,202 26,243 1,130
10 U/ml 19,983 1,042 17,414 31,602 17,741 899
Mock : 10% vol/vol 458 689 983 ND ND 510
5% vol/vol 432 432 732 43288
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FIGURE 2.
￿
Dose-effect curve of IL-4
on the response to IL-2. B-CLL cells
tss
￿
_---4
￿
fromthree patients were cultured in the
presence of anti-1A antibody + 50
U/ml of IL-2, in the absence ofIL-4,
'~
￿
or in the presence of graded concen-
trations ofIL-4. Results are expressed
i
￿
as percent inhibition by a given con-
centrationofIL-4 (mean t SEM from
'
￿
three patients). The percent ofinhibi-
tion was calculated as follow: Percent
inhibition = 1 - [cpm (cells + IL-4
+ IL-2) - cpm (cells + IL-4)1/[cpm
& .1s
￿
e x
￿
ss
￿
txs
￿
is
￿
s
￿
1s
￿
s.
￿
(cells + IL-2) - cpm (cells)). The re-
I« (u/mi)
￿
sponses in the absence of IL-4 (ex-
pressed as A cpm) were: 21,866,
33,312, and 30,240.
ofeffect in itself, might interfere with the responsiveness ofB-CLLlymphocytes to
IL-2. Cellsfrom the 10 patients respondingto costimulation byanti-P antibody and
IL-2 were selected. They were cultured for 3 d with anti-p antibody and IL-2 (50
U/ml) in the absence or presence of50 U/ml of IL-4 (Fig. 1). In all instances, IL-4
profoundly inhibited the response to IL-2 (mean suppression: 90 t 2%). These
results were obtained with a purified preparation of IL-4 in four patients (patients
1, 3, 4, and 5)aswell as acrude preparation (the sixotherpatients). Themockprep-
aration had no inhibitory effect in the six patients tested (mean suppression: 3%).
In three patients (patients 3, 4, and 9) the dose-effect curve of IL-4 was estab-
lished. B-CLL lymphocytes were stimulated with anti-p, antibody and 50 U/ml of
IL-2, and the effects of various concentrations of IL-4 were determined (Fig. 2).
The 50% inhibitory concentration of IL-4 corresponded to 1.5 U/ml. An identical
result was obtained when the inhibitory effect of IL-4 was assayed in the presence
of 5 U of IL-2 (data not shown).
Inthe same experimentsDNA synthesis was measured on day 6 in orderto verify
that IL-4 would not delay the response to IL-2. IL-4 inhibited the day 6 response
to the same extent as the day 3 response (data not shown). It should be pointed
TABLE II
IL-4 Suppresses the Response to IL-2 Alone
Cells were cultured with IL-2 (50 U/ml) (without anti-IL antibody) and in the
absence orpresence ofIL-4 (50 U/ml). Results were expressed as cpm on day 3.
` Purified IL-4 was used.
Patients IL-4
DNA synthesis
Medium IL-2
1' - 871 3,152
+ 653 654
8' - 548 5,998
+ 441 1,337
10 - 779 7,592
+ 860 1,712KARRAY ET AL.
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TABLE III
IL-4 Inhibits the Response to the Combination of IL-2 and IFN-y
Cells from patient 11 were cultured in the presence of IFN-'Y (1,000 U/ml) or
anti-p antibody (7 pg/ml). DNA synthesis was measured on day 3. Purified IL-4
was used.
out that IL-4 profoundly suppressed the response to IL-2, regardless ofits magni-
tude, even when this response was low (see Fig. 1). In the same line we verified that
IL-4 did not enhance the response to costimulation with anti-g antibody and IL-2
incells from patients unresponsive to IL-2. The cellsfrompatients2 and 6 (see Table
I) were costimulated with anti-j antibody and IL-2 in the absence or presence of
IL-4. Theirmarginal response to IL-2 was not enhanced by IL-4 (data not shown).
TheInhibitory Effect ofIL-4 Is Observed in theAbsence ofAnti-u Antibody.
￿
The previ-
ously described experiments were performed in the presence ofanti-P antibody as
this reagent is required to obtain an optimal response to IL-2 in most cases ofB-
CLL. However, in some cases IL-2 alone is able to support DNA synthesis. The
cells fromthree patients meetingthis criteria were selected in orderto examine the
interaction between IL-2 and IL-4 in the absence ofother stimulants. Cells from
these patientswere stimulated with IL-2 alone (50U/ml)in the absence orpresence
of50 U/mlofIL-4. As showninTableII, IL-2 didstimulate DNA synthesisin these
cells and this response was fully inhibitedby IL-4. In the sameconditions the super-
natants of 10-d cultures from these patients were examined for the presence of Ig.
In no instance was Ig detected, regardless ofthe presence ofIL-4. We verified that
IL-4 did not affect cell viability. At the end of a 6-d culture of B-CLL cells, the
recovery of viable cells (evaluated by Trypan blue exclusion) was determined and
expressedaspercent oftheinitialcell input. In the presence ofIL-2 (50 U/ml) alone
TABLE IV
Expression of CD25 and CD23 Antigens
' Cells from patient 8 were cultured for 24 h with: medium, 50 U/ml of IL-2,
50 U/ml of purified IL-4, or with both interleukins.
t Cells were washed and positivity was assessed by indirect immunofluorescence
and flow cytometry.
Interleukins' CD25
Cells expressing:t
CD23
Medium 12.0 5.6
IL-2 30.6 2.7
IL-4 15.4 11 .9
IL-2 + IL-4 32.9 10.9
Factors IFN-y
DNA synthesis
Anti-It antibody
Medium 490 470
IL-2 (50 U/ml) 31,388 7,422
IL-4 (50 U/ml) 489 384
IL-4 + IL-2 815 59290
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FIGURE 3 .
￿
The simultaneous presence
of IL-2 and IL-4 is necessary for inhi-
bition. Cells from patient 8 were
pretreated for 48 h (they axis) with
medium, 50 U/ml ofIL-2, or 50 U/ml
ofpurified IL-4. Cellswere washed and
cultured for3 additional days . Cultures
were performed with IL-2 (50 U/ml),
IL-4 (50 U/ml), or both interleukins .
the recovery of viable cells was 73%, to be compared with 80% in the presence of
IL-2 (50 U/ml) and IL-4 (50 U/ml).
IL-4 Inhibits the Costimulation by Interferon-y andIL-2.
￿
We previously showed (20)
that IFN-y, although in ourhands unable to supportDNA synthesisby B-CLL cells,
can in some patients enhance the responsiveness to IL-2 . We thus tested whether
IL-4 could inhibit thecostimulation ofB-CLL cells by IL-2 and IFN-y . In the pres-
ence ofIFN-y (1,000 U/ml) or anti-tt antibody, B-CLL cells were cultured with IL-
2, IL-4, and with both interleukins for 3 d . As shown in Table III, in the presence
of IL-4 the response to IL-2 and IFN-y was suppressed to the same extent as that
to IL-2 and anti-g antibody.
IL-4 Can Deliver a Positive Signal to B-CLL Cells.
￿
One of the most clear-cut early
effects of IL-4on restingB lymphocytes is theupregulation of theexpression ofCD23
antigen (16) . We thus wondered whether IL-4 was able to exert such an effect on
B-CLL cells . The cells from patient 8 were selected as they expressed a low, and
potentially upregulation-susceptible, percentage ofCD23+ cells (Table IV) . A 24-h
incubation ofthese cells with IL-4 alone induced a twofold increase in the number
ofCD23 + cells . This effect of IL-4was observed regardless of the presence of IL-2 .
Thus, these two interleukins did not interact for the expression ofCD23 . Similarly
IL-4 did not affect the enhancement of CD25 antigen by IL-2 . The cells from pa-
tient 8 were able to respond to IL-2 in the absence of anti-g antibody (see Table
II). We could thus verify that both effects of IL-4 (on CD23 expression and on the
response to IL-2) couldtake place in the same monoclonal cells . Afterpreincubation
with IL-4, these cells were extensively washed and cultured with IL-2 alone or in
the concomitant presence of IL-2 and IL-4 (Fig . 3) . Again, IL-4 suppressed the re-
sponse to IL-2 . It should be pointed out that the continuous presence of IL-4 was
required for this inhibition to take place : cells pretreated by IL-4 and cultured with
IL-2 alone were fully able to respond to this interleukin . We also verified that pretreat-
ment with IL-2 did not prevent the suppressive effect of IL-4 (Fig . 3, bottom) .
Discussion
IL-4 is an interleukin with pleiotropic effects, acting on multiple targets among
immunocompetent cells (21) . Whether used alone or in combination with anotherKARRAY ET AL.
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signal, IL-4 is able to positively affect several aspects of the B cell response. In view
of the heterogeneity of the B cell response patterns to IL-4, we decided to analyze
the effects of this interleukin on monoclonal B cells, obtained from B-CLL patients.
These cells can respond to several interleukins. They are considered as frozen at
a given differentiation step and could thus exhibit a dissociated responsiveness to
some of the effects of IL-4. They probably arise from a discrete subpopulation of
normal B cells of which they may be representative.
One o£ the most conspicuous effects of Il-4 on human as well as murine B cells
is the enhancement of anti-Ft-induced DNA synthesis (1, 14). In a first series of ex-
periments we tested whetherthis effect could be demonstrated on B-CLLcells. Nega-
tive resultswere obtained with cells from 12 different patients even at IL-4 concen-
trations up to 100 U/ml. We verified that this lack ofresponse wasnotdueto a delayed
peak of DNA synthesis andwas not associated with aterminal differentiation. This
unresponsiveness was apparent in two-step incubation experiments, regardless of
the reagent used initially. It could not be attributed to the inefficiency of the signal
provided by anti-p antibody, as cells from 10 patients did respond to costimulation
with IL-2 and anti-p antibody. Thus, in contrast to normal polyclonal B cells, B-
CLL cells do not respond to anti-p antibody and IL-4 by an increased DNA syn-
thesis. This couldbe linked to themalignanttransformation or couldindicate adifferent
responsiveness of the normal B cell subset from which B-CLL cells arise.
IL-2 is able to enhance DNA synthesis by cells from most B-CLL patients (17,
22, 23). Moreover, in selected patients the effects ofthis interleukin can be enhanced
by IFN-y (22) and/or IFN-a (18). Thus, monoclonal B cells provide suitable targets
to search for synergy between interleukins. We examined the interactions between
IL-4 and IL-2. IL-4 profoundly and constantly suppressed the response to IL-2 in
all patient responders to this interleukin. This effect was obtained with low concen-
trations of IL-4 with a 50% inhibitory concentration of 1.5 U/ml. It was not ob-
served with mock preparations of IL-4, and this effect could be demonstrated with
a preparation of IL-4 purified to homogeneity. It was not attributable to a delayed
DNA synthesis and did not result in terminal differentiation.
These results indicated a negative interaction between IL-4 and IL-2 itself. In-
deed they could be obtained in three different experimental conditions: (a) When
an optimal response to IL-2 was obtained by costimulation with anti-A antibody;
(b) when IL-2 was used alone, in these B-CLL cells able to respond to this inter-
leukin in the absence of first signal (17); and(c)when a synergistic response to IL-2
and IFN-y (20) took place. This latter result is important in view of the previously
reported interaction between IFN-y and IL-4 (14, 16).
This negative interaction between IL-4 and IL-2 was unexpected in view of the
synergy between these interleukins on T cell proliferative response (15). However,
it fits with two recently publishedsets ofdata. IL-4 inhibits thedevelopment ofcyto-
toxic effector cells that occurs in response to IL-2 (24). IL-4 inhibits the growth of
bone marrow-derived pre-Bcells (12). As discussedearlier, B-CLLlymphocytes might
be representive of a minor normal B lymphocyte population exhibiting an unusual
responsiveness to IL-4. This is supported by the observation that IL-4, although
able to enhance DNA synthesis by normal polyclonal B cells, partially suppresses
the IL-2-dependent proliferation of these cells (Defrance, T., et al., manuscript sub-
mitted for publication).92
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Another early effect of IL-4 on normal resting B cells is the upregulation of the
expression of CD23 (16, 25, 26). We thus examined whether this effect could take
place in B-CLL lymphocytes. To address this question we selected cells from one
patient on the basis of the following criteria: (a) These cells expressed low levels of
CD23 andwere thus potentially susceptible to upregulation; and (b)these cells were
responsive to IL-2 in the absence of anti-p antibody, allowing the studyofthe inter-
action between both interleukins. The incubation with IL-4 induced an upregula-
tion of CD23, showing that IL-4 could positively act on these monoclonal B cells.
This contrasted with the profound negative effect of IL-4 on the proliferative re-
sponse of the same cells to IL-2. The relationships between these two effects of IL-4
are not yet understood. The preincubation of B-CLL cells with IL-4 neither pre-
ventstheirsubsequent responsiveness to IL-2 (provided IL-4 is removed) nor inter-
feres with the upregulation of CD25 expression by IL-2 itself (see Table IV). Fur-
ther studies are required to analyze the mechanisms of this negative interaction of
IL-4 and IL-2 on the same target B cell.
Our results have important implications for the definition of the effects of IL-4
on B cells. Subsets of B lymphocytes may be insensitive to the growth-promoting
effect of IL-4. More importantly, IL-4 can counteract the effects of IL-2 on B cell
proliferation. As most B-CLL cells respond in vitro to IL-2, this antagonism should
be taken into account when evaluating the therapeutic perspectives offered by the
use of cytokines in B-CLL patients.
Summary
B cells from patients sufferingfrom B-type chronic lymphocytic leukemia (B-CLL)
are susceptible to the effects of several interleukins. Usingthe cells from 12 different
patients we show that IL-4 does not synergize with anti-p antibody for the enhance-
ment of DNA synthesis. Moreover IL-4 profoundly (90%) suppresses the response
to IL-2 in the 10 patient responders to this interleukin. This suppression occurs whether
IL-2 is used alone, in costimulation with anti-Ft antibody, or in synergy with IFN-y.
In no instance did IL-4 induce terminal differentiation. This negative effect of IL-4
can take place in monoclonal B-CLL cells where IL-4 enhances the expression of
CD23. IL-4 does not interfere with the upregulation of CD25 by IL-2. Thus, IL-4
may display inhibitory effects on the proliferative response ofselected B cell popula-
tions. The antagonism between IL-4 and IL-2 has important implications for the
potential use of cytokines in the management of B-CLL patients.
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